Home › Funds › Monaco Asset Management SAM › LKFT
Monaco Asset Management SAM position in LKFT
LAKEFRONT BIOTHERAPEUTICS NV
Monaco Asset Management SAM reported holding 20,000 shares of LKFT (LAKEFRONT BIOTHERAPEUTICS NV) in its Q3 2026 13F filing — a position valued at US$593K, representing 0.08% of its reported portfolio and ranking #38 among its reported holdings. Monaco Asset Management SAM has disclosed LKFT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Monaco Asset Management SAM's LKFT position evolved
Monaco Asset Management SAM first disclosed a stake in LKFT in Q3 2023 at 8,458 shares (US$292K). The position peaked in Q3 2025 at 33,536 shares, worth US$1.2M. Across 13 filings, Monaco Asset Management SAM increased the stake 3 time(s), trimmed it 7 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 20,000 shares valued at US$593K — a reduction of -5,600 shares quarter over quarter.. Notable position changes include a 148% increase in Q1 2024 (shares fell 23% over the following quarter), a 29% trim in Q4 2024 (shares fell 9% over the following quarter), a 140% increase in Q1 2025 (shares rose 11% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 8.46K | $292.22K | New |
| Q4 2023 | 6.74K | $274.14K | Reduce |
| Q1 2024 | 16.74K | $539.16K | Add |
| Q2 2024 | 21.00K | $520.36K | Add |
| Q3 2024 | 21.00K | $604.56K | Hold |
| Q4 2024 | 15.00K | $412.50K | Reduce |
| Q1 2025 | 36.04K | $905.22K | Add |
| Q2 2025 | 36.04K | $1.01M | Hold |
| Q3 2025 | 33.54K | $1.16M | Reduce |
| Q4 2025 | 32.52K | $1.06M | Reduce |
| Q1 2026 | 27.52K | $825.60K | Reduce |
| Q2 2026 | 25.60K | $767.49K | Reduce |
| Q3 2026 | 20.00K | $593.00K | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About LKFT and 13F data
LKFT (LAKEFRONT BIOTHERAPEUTICS NV) is a company whose sector is not yet classified in our data. 19 other funds we track also report a position in LKFT — the largest reported positions include GILEAD SCIENCES, INC. (US$501.3M), TANG CAPITAL MANAGEMENT LLC (US$113.5M), Madison Avenue Partners, LP (US$103.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding LKFT
- GILEAD SCIENCES, INC. 16.71M sh · $501.28M · Q3 2026
- TANG CAPITAL MANAGEMENT LLC 3.79M sh · $113.50M · Q2 2026
- Madison Avenue Partners, LP 3.45M sh · $103.37M · Q2 2026
- Prosight Management, LP 2.04M sh · $61.26M · Q2 2026
- EcoR1 Capital, LLC 1.67M sh · $49.98M · Q2 2026
- DME Capital Management, LP 482.75K sh · $14.47M · Q2 2026
- DAFNA Capital Management LLC 130.18K sh · $3.90M · Q2 2026
More on Monaco Asset Management SAM
FAQ
How long has Monaco Asset Management SAM held LKFT?
Monaco Asset Management SAM has disclosed LKFT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Monaco Asset Management SAM's current position in LKFT?
As of Q3 2026, Monaco Asset Management SAM holds 20.00K shares of LKFT (LAKEFRONT BIOTHERAPEUTICS NV), valued at $593.00K, representing 0.08% of its reported portfolio and ranking #38.
Has Monaco Asset Management SAM been buying or selling LKFT?
In the latest 13F filing (Q3 2026), Monaco Asset Management SAM reduced its position in LKFT. The position peaked in Q3 2025 at 33.54K shares.
Which other funds hold LKFT?
Other major institutional holders of LKFT include GILEAD SCIENCES, INC., TANG CAPITAL MANAGEMENT LLC, Madison Avenue Partners, LP, among 19 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.